![]() |
|||||||||||||
|
All | Since 2019 | |
Citation | 5450 | 3969 |
h-index | 23 | 20 |
i10-index | 134 | 84 |
CURRENT TRENDS IN PHARMACOLOGICAL APPLICATIONS OF SARTANS
Dobrina D. Tsvetkova*, Danka P. Obreshkova, Stefka A. Ivanova, Vladimir P. Yankov, Peter Atanasov and Valentina B. Petkova
ABSTRACT The aim of current study is to summarize the application of sartans for thetapy of hypertension and related cardiovascular diseases. Arterial hypertension is a widespread disease with more than 1 billion cases worldwide. Hypertension is one of the most significant social disease, leading to stroke, myocardial infarction and high mortality. A major advantage of sartans in comparison with ACE-inhibitors in the treatment of essential hypertension, is that not inhibit the degradation of bradykinin and other kinins and thus not cause the side effects (cough and angioedema) of ACE-inhibitors. Sartans are applied in a number of heart diseases: heart failure, atrial fibrillation, hypertension with left ventricular dysfunction, acute coronary syndrome, for protection of vascular endothelium and platelet aggregation, for prevention of stroke, cerebral ischemia, Alzheimer, Parkinson; and migraine. Blood pressure control is optimized by fixed-dose formulations of sartans with thiazide diuretic Hydrochlorothiazide (HCTZ): Candesartan (Atacand HCT), Irbesartan (Avapro HCT), Olmesartan medoxomil (Benicar HCTZ), Valsartan (Со-Valsacor). Keywords: sartans, pharmacological application, clinical trials, combinations [Download Article] [Download Certifiate] |